Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma

• Published in: CNS neuroscience & therapeutics Vol. 30; no. 6; pp. e14802 - n/a
• Main Authors: Chen, Junyi, Liu, Yuyang, Lan, Jinxin, Liu, Hongyu, Tang, Qingyun, Li, Ze, Qiu, Xiaoguang, Hu, Wentao, Xie, Jiaxin, Feng, Yaping, Qin, Lilin, Zhang, Xin, Liu, Jialin, Chen, Ling
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.06.2024; John Wiley and Sons Inc
• Subjects: AKT protein; Animals; Antitumor activity; Brain cancer; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Brain research; Brain tumors; Cancer therapies; Cell culture; Cell cycle; Cell Line, Tumor; Chemotherapy; COL6A1; Collagen Type VI - genetics; Collagen Type VI - metabolism; Electric fields; Electric Stimulation Therapy - methods; Extracellular matrix; Functional morphology; Gene expression; Genomes; Genomics; Glioblastoma; Glioblastoma - genetics; Glioblastoma - metabolism; Glioblastoma - therapy; glioblastoma multiforme; Glioma; Glioma cells; Humans; Immunofluorescence; Immunoprecipitation; Localization; Medical prognosis; Metastasis; Mice; Mice, Nude; Ontology; Original; Paxillin; Proteins; Therapeutic targets; tumor electric field therapy; glioblastoma multiforme; tumor electric field therapy; extracellular matrix; COL6A1
• ISSN: 1755-5930; 1755-5949; 1755-5949
• DOI: 10.1111/cns.14802

Background Glioblastoma multiforme (GBM) is the most aggressive primary brain malignancy. Novel therapeutic modalities like tumor electric field therapy (TEFT) have shown promise, but underlying mechanisms remain unclear. The extracellular matrix (ECM) is implicated in GBM progression, warranting investigation into TEFT‐ECM interplay. Methods T98G cells were treated with TEFT (200 kHz, 2.2 V/m) for 72 h. Collagen type VI alpha 1 (COL6A1) was identified as hub gene via comprehensive bioinformatic analysis based on RNA sequencing (RNA‐seq) and public glioma datasets. TEFT intervention models were established using T98G and Ln229 cell lines. Pre‐TEFT and post‐TEFT GBM tissues were collected for further validation. Focal adhesion pathway activity was assessed by western blot. Functional partners of COL6A1 were identified and validated by co‐localization and survival analysis. Results TEFT altered ECM‐related gene expression in T98G cells, including the hub gene COL6A1. COL6A1 was upregulated in GBM and associated with poor prognosis. Muti‐database GBM single‐cell analysis revealed high‐COL6A1 expression predominantly in malignant cell subpopulations. Differential expression and functional enrichment analyses suggested COL6A1 might be involved in ECM organization and focal adhesion. Western blot (WB), immunofluorescence (IF), and co‐immunoprecipitation (Co‐IP) experiments revealed that TEFT significantly inhibited expression of COL6A1, hindering its interaction with ITGA5, consequently suppressing the FAK/Paxillin/AKT pathway activity. These results suggested that TEFT might exert its antitumor effects by downregulating COL6A1 and thereby inhibiting the activity of the focal adhesion pathway. Conclusion TEFT could remodel the ECM of GBM cells by downregulating COL6A1 expression and inhibiting focal adhesion pathway. COL6A1 could interact with ITGA5 and activate the focal adhesion pathway, suggesting that it might be a potential therapeutic target mediating the antitumor effects of TEFT. Innovative TEFT therapeutic target COL6A1 in GBM.